Conatus Pharmaceuticals Gets a Buy Rating from H.C. Wainwright

By Carrie Williams

In a report released today, Ed Arce from H.C. Wainwright reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT), with a price target of $18. The company’s shares closed yesterday at $5.60.

According to, Arce is a 5-star analyst with an average return of 25.6% and a 49.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Sucampo Pharmaceuticals.

Currently, the analyst consensus on Conatus Pharmaceuticals is Strong Buy and the average price target is $12.75, representing a 127.7% upside.

In a report issued on June 16, Stifel Nicolaus also reiterated a Buy rating on the stock with a $10 price target.

Based on Conatus Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $7 million and GAAP net loss of $3.62 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $6.47 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Conatus Pharmaceuticals, Inc. is a biotechnology company that engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in Dan Diego, CA.